Development of Novel DDS Technologies for Optimized Protein Therapy by Creating Functional Mutant Proteins with Antagonistic Activity

DOI Web Site Web Site 23 References
  • ABE Yasuhiro
    Laboratory of Pharmaceutical Proteomics, National Institute of Biomedical Innovation

Bibliographic Information

Other Title
  • タンパク療法の最適化に向けた新規タンパク性アンタゴニストの創製とDDSへの展開
  • タンパク リョウホウ ノ サイテキカ ニ ムケタ シンキ タンパクセイ アンタゴニスト ノ ソウセイ ト DDS エ ノ テンカイ

Search this article

Description

  In the post-genomic era, cytokine or antibody therapy has received attention for advanced drug therapies. Indeed, attempts are being made to develop a wide variety of therapeutic proteins for diseases including cancer, hepatitis and autoimmune conditions. Unfortunately, however, the utilization of bioactive proteins in clinical practice is often limited because of their inherent instability and pleiotropic actions in vivo. Our laboratory aims to overcome two major problems, details of which will be addressed in separate sections to follow. (i) Development of a powerful system to rapidly create functional mutant proteins (muteins) with enhanced receptor affinity and receptor specificity using a phage display technique (biological DDS). (ii) Establishment of a novel polymer-conjugation system to dramatically improve in vivo stability and selectively of bioactive proteins (polymeric DDS). We are currently attempting to combine both approaches to create a protein-drug innovation system to further promote pharmaco-proteomic-based drug development. In this review, we will describe DDS-based technology for creating functional mutants for advanced medical applications, using tumor necrosis factor-alpha (TNF) as an example.<br>

Journal

  • YAKUGAKU ZASSHI

    YAKUGAKU ZASSHI 129 (8), 933-939, 2009-08-01

    The Pharmaceutical Society of Japan

References(23)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top